Patient perspectives on the treatment burden of injectable medication for hereditary angioedema

Allergy Asthma Proc. 2021 May 1;42(3):S4-S10. doi: 10.2500/aap.2021.42.210025.

Abstract

Hereditary angioedema (HAE) is a rare, chronic disease characterized by debilitating swelling episodes in various parts of the body. Patients experience significant burdens related to the symptoms and management of HAE, which can affect their daily lives and reduce their overall quality of life. Prophylactic treatment options have expanded in the past decade to the benefit of patients; however, these therapies require scheduled injections, which can be painful, burdensome, and time consuming. We conducted an online survey of patients with HAE in the USA to better understand their experiences with available prophylactic medications and the associated treatment burdens. Our survey results suggest that most patients are satisfied with their current therapies but desire novel medications with a simpler route of administration and that, although most patients experience significant treatment-related burdens, they learn to cope with these challenges over time.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angioedemas, Hereditary* / diagnosis
  • Angioedemas, Hereditary* / drug therapy
  • Edema
  • Humans
  • Injections
  • Quality of Life
  • Surveys and Questionnaires